

**Final - February 23, 2022**

**MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)**

Centers for Disease Control and Prevention

Atlanta, Georgia 30329

February 23-24, 2022

**Wednesday, February 23, 2022**

<b>10:00</b>	<b>Welcome &amp; Introductions</b>	Dr. Grace Lee (ACIP Chair) Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
<b>10:20</b>	<b>Tickborne Encephalitis (TBE) Vaccine</b> Introduction Review of considerations for use of TBE vaccine in travelers and laboratorians Proposed recommendations	Dr. Katherine Poehling (ACIP WG Chair) Dr. Susan Hills (CDC/NCEZID) Dr. Susan Hills (CDC/NCEZID)
<b>11:15</b>	<b>Cholera Vaccine</b> Introduction Clinical considerations for use of cholera vaccine in children and adolescents aged 2–17 years Proposed recommendations	Dr. Pablo Sanchez (ACIP, WG Chair) Dr. Jennifer Collins (CDC/NCEZID) Dr. Jennifer Collins (CDC/NCEZID)
<b>11:50</b>	<b><i>Break</i></b>	
<b>12:10</b>	<b>Influenza Vaccine</b> Introduction Influenza activity update Recommending enhanced seasonal influenza vaccines in adults age 65 and older--potential impacts on influenza burden Influenza vaccines for older adults	Dr. Keipp Talbott (ACIP, WG Chair) Dr. Lisa Grohskopf (CDC/NCIRD) Dr. Sinead Morris (CDC/NCIRD) Dr. Lisa Grohskopf (CDC/NCIRD)
<b>1:10</b>	<b>Hepatitis Vaccine</b> Introduction PREHEVBRIO for adult HepB vaccination: EtR and GRADE	Dr. Kevin Ault (ACIP, WG Chair) Dr. Mark Weng (CDC/NCHHSTP)
<b>1:40</b>	<b><i>Break</i></b>	
<b>1:55</b>	<b>MMR Vaccine Workgroup</b> Introduction MMR safety and immunogenicity	Ms. Lynn Bahta (ACIP, WG Chair) Dr. Remon Abu-Elyazeed (GSK)
<b>2:25</b>	<b>Public Comment</b>	
<b>2:45</b>	<b><u>VOTE</u></b> <b>TBE Vaccine</b> <b>Cholera Vaccine</b>	Dr. Susan Hills (CDC/NCEZID) Dr. Jennifer Collins (CDC/NCEZID)
<b>4:00</b>	<b>Adjourn</b>	

**Thursday, February 24, 2022**

<b>10:00</b>	<b>Welcome &amp; Introductions</b>	Dr. Grace Lee (ACIP Chair) Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
<b>10:10</b>	<b>Agency Updates</b> CDC, CMS, FDA, HRSA, HIS, OIDP, NIH	
<b>10:25</b>	<b>Pneumococcal Vaccines</b> Introduction Epidemiology of pneumococcal disease and pneumococcal vaccine coverage in US children PCV15 Phase 2/3 study results in children GRADE and EtR for PCV15 use in U.S. children Summary and next steps	Dr. Katherine Poehling (ACIP, WG Chair) Mr. Ryan Gierke (CDC/NCIRD) Dr. Natalie Bannettis (Merck) Ms. Jennifer Farrar (CDC/NCIRD) Dr. Miwako Kobayashi (CDC/NCIRD)
<b>12:15</b>	<b>Adjourn</b>	

**Acronyms**

CDC	Centers for Disease Control and Prevention
CMS	Centers for Medicare and Medicaid Services
COVID-19	Coronavirus disease 2019
EtR	Evidence to Recommendations Framework
FDA	Food and Drug Administration
GRADE	Grading of Recommendations Assessment, Development and Evaluation
HRSA	Health Resources and Services Administration
IHS	Indian Health Service
NCHHSTP	National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]
NCIRD	National Center for Immunization & Respiratory Diseases [of CDC/OID]
NCEZID	National Center for Emerging and Zoonotic Diseases [of CDC/OID]
NIAID	National Institute of Allergy and Infectious Diseases
OIDP	Office of Infectious Disease and HIV/AIDS Policy
SARS-CoV-2	Severe Acute Respiratory Syndrome Coronavirus 2
WG	Work Group
WHO	World Health Organization
VE	Vaccine Effectiveness